The risk of upper gastrointestinal (GI) adverse events of patients switching from risedronate to alendronate after the introduction of generic alendronate products in the UK

✍ Scribed by S.H. Ralston; T.D. Kou; B.C. Wick-Urban; M. Steinbuch

• Book ID: 116321359
• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 68 KB
• Volume: 44
• Category: Article
• ISSN: 8756-3282
• DOI: 10.1016/j.bone.2009.01.252